PSMA-PET scans detect metastatic illness in 46% of sufferers with high-risk nonmetastatic hormone-sensitive prostate most cancers, revealing understaging by standard imaging.Amongst sufferers with...
March is Myeloma Consciousness Month, a time to acknowledge the refined however severe signs of a number of myeloma, together with persistent fatigue,...
The potential Meals and Drug Administration approval of Ordspono (odronextamab) for relapsed or refractory follicular lymphoma (FL) was mentioned by Dr. Deepa Jagadeesh,...
